Interview with Harald Stock, CEO, Grünenthal
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Address: Werner-von-Siemens-Straße 22-28
64625 Bensheim
Tel: +49 (0) 6251 – 1083-0
Web: http://www.koehler-chemie.de/deutsch/startseite/
Dr. Franz Köhler Chemie, the company, specialises in organ-protecting solutions, therapeutics, x-ray contrast agents and antidotes. On this basis, Dr. Gernot Köhler, from the second generation, has expanded the company into an innovative, research-intensive and high performance pharmaceuticals company in Alsbach, the USA and Russia. Distributing associates represent the company worldwide. Internal research makes innovative products and continuous development possible. As a result, new therapeutic approaches are formulated in close co-operation with qualified doctors and research is carried out effectively and dependent on requirements. “We are at your service” is the mission statement with which we shall continue to contribute to advances in science and medicine in the interests of the user and patients alike.
Dr. Franz Josef Köhler founded the company in 1959. He is the founder of aspartic therapy and a promoter of organ-protecting solutions. In his honour, the German Society for Thoracic and Cardiovascular Surgery has awarded the “Franz J. Köhler Award” every year since 1990, for outstanding work in the field of organ protection with special emphasis on the heart. His son, Dr. Gernot Köhler, has headed this modern medium sized company since 1984, guiding it into new areas of business.
Dr. Franz Köhler Chemie produces at two German locations thereby meeting the increasing international demand for organ-protecting solutions. The products, perfusion, infusion and injection solutions from Alsbach and Bensheim in South Hesse are in a leading position internationally.
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Roche, once a true pharmaceutical company, is now recognized by its capacity to create a unique business model that allowed to become the world’s largest biotech company with truly differentiated…
Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The…
Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community.…
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
See our Cookie Privacy Policy Here
